Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1957 Dec;16(4):425–437. doi: 10.1136/ard.16.4.425

Evaluation of Uricosuric Agents in Chronic Gout *

M A Ogryzlo 1,2, Joan Harrison 1,2,†
PMCID: PMC1006984  PMID: 13498593

Full text

PDF
425

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARTELS E. C. Gout--now amenable to control. Ann Intern Med. 1955 Jan;42(1):1–10. doi: 10.7326/0003-4819-42-1-1. [DOI] [PubMed] [Google Scholar]
  2. BAUER W., SINGH M. M. Management of gout. N Engl J Med. 1957 Jan 31;256(5):214–concl. doi: 10.1056/NEJM195701312560505. [DOI] [PubMed] [Google Scholar]
  3. BENEDICT J. D., FORSHAM P. H., ROCHE M., SOLOWAY S., STETTEN D., Jr The effect of salicylates and adrenocorticotropic hormone upon the miscible pool of uric acid in gout. J Clin Invest. 1950 Aug;29(8):1104–1111. doi: 10.1172/JCI102343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BISHOP C., BEECHER L. Effect of phenylbutazone on uric acid excretion in patients with gout and rheumatoid arthritis. Proc Soc Exp Biol Med. 1953 Jul;83(3):603–605. doi: 10.3181/00379727-83-20432. [DOI] [PubMed] [Google Scholar]
  5. BISHOP C., RAND R., TALBOTT J. H. The effect of benemid (P-[DI-N-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject. J Clin Invest. 1951 Aug;30(8):889–895. doi: 10.1172/JCI102505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. BOGER W. P., STRICKLAND S. C. Probenecid (benemid); its uses and side-effects in 2,502 patients. AMA Arch Intern Med. 1955 Jan;95(1):83–92. doi: 10.1001/archinte.1955.00250070099012. [DOI] [PubMed] [Google Scholar]
  7. BRODIE B. B., LOWMAN E. W., BURNS J. J., LEE P. R., CHENKIN T., GOLDMAN A., WEINER M., STEELE J. M. Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone. Am J Med. 1954 Feb;16(2):181–190. doi: 10.1016/0002-9343(54)90333-2. [DOI] [PubMed] [Google Scholar]
  8. BRODIE B. B., YU T. F., BURNS J. J., CHENKIN T., PATON B. C., STEELE J. M., GUTMAN A. B. Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione). Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):884–887. doi: 10.3181/00379727-86-21263. [DOI] [PubMed] [Google Scholar]
  9. BURNS J. J., YU T. F., RITTERBAND A., PEREL J. M., GUTMAN A. B., BRODIE B. B. A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther. 1957 Mar;119(3):418–426. [PubMed] [Google Scholar]
  10. GUTMAN A. B., YU T. F., RANDOLPH V. Further observation on the uricosuric effects of probenecid (benemid) in tophaceous gout. Trans Assoc Am Physicians. 1954;67:250–260. [PubMed] [Google Scholar]
  11. KUZELL W. C., SCHAFFARZICK R. W., NAUGLER W. E., GAUDIN G., MANKLE E. A., BROWN B. Phenylbutazone (butazolidin) in gout. Am J Med. 1954 Feb;16(2):212–217. doi: 10.1016/0002-9343(54)90336-8. [DOI] [PubMed] [Google Scholar]
  12. KUZELL W. C., SCHAFFARZICK R. W., NAUGLER W. E., KOETS P., MANKLE E. A., BROWN B., CHAMPLIN B. Some observations on 520 gouty patients. J Chronic Dis. 1955 Dec;2(6):645–669. doi: 10.1016/0021-9681(55)90193-4. [DOI] [PubMed] [Google Scholar]
  13. MARSON F. G. W. Radiological evidence of the value of treatment in gout. Br J Radiol. 1952 Oct;25(298):539–541. doi: 10.1259/0007-1285-25-298-539. [DOI] [PubMed] [Google Scholar]
  14. MAUER E. F. The toxic effects of phenylbutazone (butazolidin); review of the literature and report of the twenty-third death following its use. N Engl J Med. 1955 Sep 8;253(10):404–410. doi: 10.1056/NEJM195509082531003. [DOI] [PubMed] [Google Scholar]
  15. PASCALE L. R., DUBIN A., HOFFMAN W. S. Therapeutic value of probenecid (benemid) in gout. J Am Med Assoc. 1952 Jul 26;149(13):1188–1194. doi: 10.1001/jama.1952.02930300014004. [DOI] [PubMed] [Google Scholar]
  16. SIROTA J. H., YU T. F., GUTMAN A. B. Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects. J Clin Invest. 1952 Jul;31(7):692–701. doi: 10.1172/JCI102651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. SOUGIN-MIBASHAN R., HORWITZ M. The uricosuric action of ethyl biscoumacetate. Lancet. 1955 Jun 11;268(6876):1191–1197. doi: 10.1016/s0140-6736(55)90691-7. [DOI] [PubMed] [Google Scholar]
  18. TALBOTT J. H., BISHOP C., NORCROSS B. M., LOCKIE L. M. The clinical and metabolic effects of benemid in patients with gout. Trans Assoc Am Physicians. 1951;64:372–377. [PubMed] [Google Scholar]
  19. URIC acid metabolism and gout. Am J Med. 1950 Dec;9(6):799–817. doi: 10.1016/0002-9343(50)90293-2. [DOI] [PubMed] [Google Scholar]
  20. WILSON G. M., Jr, HUFFMAN E. R., SMYTH C. J. Oral phenylbutazone in the treatment of acute gouty arthritis. Am J Med. 1956 Aug;21(2):232–236. doi: 10.1016/0002-9343(56)90056-0. [DOI] [PubMed] [Google Scholar]
  21. WYNGAARDEN J. B. The effect of phenylbutazone on uric acid metabolism in two normal subjects. J Clin Invest. 1955 Feb;34(2):256–262. doi: 10.1172/JCI103078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. YU T. F., PATON B. C., CHENKIN T., BURNS J. J., BRODIE B. B., GUTMAN A. B. Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent. J Clin Invest. 1956 Apr;35(4):374–385. doi: 10.1172/JCI103288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. YU T. F., SIROTA J. H., GUTMAN A. B. Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects. J Clin Invest. 1953 Nov;32(11):1121–1132. doi: 10.1172/JCI102836. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES